Stereotactic radiation for limited spread in kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed clear cell kidney cancer (sometimes mixed with other types).
- Your scans show metastases outside the brain (extracerebral), and only 1–3 growing spots.
- The growing spots are in up to 2 organs and have been confirmed on two CT scans about 2 months apart.
- At least one of the growing metastases is measurable on scan, and each target spot is 4 cm or smaller.
- Your overall health is good enough for treatment (WHO performance status 0–2) and you must be able to receive stereotactic radiation to all growing sites.
- You must be able to continue the usual cancer drugs and to be followed up; age 18+ and able to give consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
This study is testing whether high-dose radiation therapy can safely treat kidney cancer that has spread to a few spots in the body, either when it is first found or when it grows during standard drug treatment. The goal is to see if this approach is effective and well-tolerated.
This trial tests whether adding radiation to standard drug therapy helps control kidney cancer that has spread to a few spots (oligometastatic). It is for people with clear cell renal cell carcinoma who have up to 5 metastases.
This trial tests a precise type of radiation therapy for small, early-stage kidney tumors that cannot be surgically removed or are at high risk for surgery. It aims to offer an alternative treatment with fewer side effects.
This trial uses a precise, high-dose radiation technique (called stereotactic body radiation therapy) that tracks and treats kidney tumors while you breathe. It aims to destroy tumors without surgery, potentially offering a less invasive option for people who cannot or prefer not to have an operation.
Hear when a new Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.